Gandara DR, Von Pawel J, Sullivan RN, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001).
Prognostische communicatie bij palliatieve kankerzorg: het belang van woorden én cijfers
feb 2024